Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay-Reference-Cited by-同舟云学术

Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay

Published:1994-03 Issue:3 Volume:24 Page:765-768
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Stuber György,Leder Gerhard H.,Storkus Walter J.,Lotze Michael T.,Modrow Susanne,Székely László,Wolf Hans,Klein Eva,Kärre Klas,Klein George

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference20 articles.

1. p53 Mutations in Human Cancers

2. The p53 tumour suppressor gene

3. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.

4. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumoursin situ andin vitro

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered HCMV‐infected APCs enable the identification of new immunodominant HLA‐restricted epitopes of anti‐HCMV T‐cell immunity;HLA;2024-06

2. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy;Science Translational Medicine;2024-01-17

3. Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations;Biomedicine & Pharmacotherapy;2023-12

4. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy;Cancer Cell;2022-09

5. Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines;The Journal of Immunology;2021-04-28